Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial
The Journal of Clinical Hypertension · 2023
DOI: 10.1111/jch.14707 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Eun Joo Cho und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, Catholic University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Hypertension, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double‐blind, active‐controlled, phase 3, randomized trial. Patients are randomized to triple combination (telmisartan 40 mg/amlodipine 5 mg/chlorthalidone 12.5 mg, TEL/AML/CHTD group) or dual combination (telmisartan 40 mg/amlodipine 5 mg, TEL/AML group) treatment and then dose up titration to TEL 80/AML5/CHTD25mg and TEL80/AML5, respectively. The primary endpoint is the change of mean sitting systolic blood pressure (MSSBP) at week 8. A Target BP achievement rate, a response rate, and the safety endpoints are also evaluated. Total 374 patients (mean age = 60.9 ± 10.7 years, male = 78.3%) were randomized to the study. The baseline MSSBPs/diastolic BPs were 149.9 ± 12.2/88.5 ± 10.4 mm Hg. After 8 weeks treatment, the change of MSSBPs at week 8 are −19.1 ± 14.9 mm Hg (TEL/AML/CHTD) and −11.4 ± 14.7 mm Hg (TEL/AML) ( p < .0001). The achievement rates of target BP (53.8% vs. 37.8%, p = .0017) and responder rate (54.8% vs. 35.6%, p = .0001) at week 8 were significantly higher in TEL/AML/CHTD. There are no serious adverse event and no one discontinued medication due to adverse event. Among the TEL 80/AML5/CHTD25mg treatment group, patients of female or age ≥ 65 years old showed higher rate of target BP achievement than relatively young male. (61.4 vs. 46.8%, p = .042) Our study showed standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg is efficacious and safe in treatment of primary hypertension. Target BP achievement with triple therapy would be facilitated in female or old age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, Catholic University College of Medicine, Seoul, South Korea.
- Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, South Korea.
- Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University College of Medicine, Seoul, South Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
- Division of Cardiology, Department of Internal Medicine, Gil Hospital, Gachon University College of Medicine, Incheon, South Korea.
ORCID-Profile: Jinho Shin, Moo-Yong Rhee, Hyo-Soo Kim
Zitieren
APA
Cho, E. J., Kim, M. H., Kim, Y. H., Chang, K., Choi, D. J., Kang, W. C., Shin, J., Kim, S. H., Lee, N., Son, J. W., Doh, J. H., Kim, W. S., Hong, S. J., Rhee, M. Y., Ahn, Y., Lim, S. W., Hong, S. P., Choi, S. Y., Hyon, M. S., …, & Kim, H. S. (2023). Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14707
Vancouver
Cho EJ, Kim MH, Kim YH, Chang K, Choi DJ, Kang WC, et al. Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14707
BibTeX
@article{Cho2023,
author = {Cho, Eun Joo and Kim, Moo Hyun and Kim, Young-Hak and Chang, Kiyuk and Choi, Dong-Ju and Kang, Woong Chol and Shin, Jinho and Kim, Seong Hwan and Lee, Namho and Son, Jang Won and Doh, Joon-Hyung and Kim, Woo-Shik and Hong, Soon Jun and Rhee, Moo-Yong and Ahn, Youngkeun and Lim, Sang-Wook and Hong, Seung Pyo and Choi, So-Yeon and Hyon, Min Su and Hwang, Jin-Yong and Kwon, Kihwan and Cha, Kwang Soo and Ihm, Sang-Hyun and Lee, Jae-Hwan and Yoo, Byung-Su and Kim, Hyo-Soo},
title = {Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial},
journal = {The Journal of Clinical Hypertension},
year = {2023},
doi = {10.1111/jch.14707}
}
EUVIMED